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SUMMARY: Current research suggests that virgin olive oil (VOO) phenolics are potent preventive and therapeutic agents against 
metabolic diseases associated with inflammation and oxidative stress. Evidence-based medicine requires these effects be proved in 
randomized controlled trials (RCT), which are then assessed in meta-analyses, to ensure that the alleged health benefits really proceed in 
humans. The available evidence is limited to the ability of VOO phenolic compounds to protect lipoproteins from oxidation and to reduce 
systolic pressure in hypertensive individuals. No RCT assessing the effects of VOO phenolics on diabetes and neurodegenerative diseases 
have been performed, and those focused on osteoarthritis and cancer provided very scarce information. Therefore, RCT in extensive and 
diverse population groups, with different disorders and phenolic doses adjusted to usual VOO consumptions are necessary to achieve high 
quality scientific evidence before nutritional recommendations can be given to the general public.
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RESUMEN: Efectos de los compuestos fenólicos del aceite de oliva virgen en la salud: ¿evidencia sólida o simplemente otro fiasco? 
Las investigaciones actuales indican que los compuestos fenólicos del aceite de oliva virgen (AOV) son potentes agentes preventivos y 
terapéuticos contra las enfermedades metabólicas asociadas con la inflamación y el estrés oxidativo. La medicina basada en la evidencia 
requiere que estos efectos se prueben en ensayos aleatorizados controlados (RCT), que son después evaluados en meta-análisis, para 
garantizar que los supuestos beneficios para la salud realmente se registran en humanos. La evidencia disponible se limita a la capacidad de 
los compuestos fenólicos del AOV para proteger las lipoproteínas de la oxidación y reducir la presión sistólica en individuos hipertensos. 
No se han realizado RCT que evalúen el efecto de estos compuestos sobre la diabetes y las enfermedades neurodegenerativas, y los que 
se centraron en la osteoartritis y el cáncer han proporcionado información muy escasa. Por lo tanto, nuevos RCT, en grupos de población 
extensos y diversos, con diferentes patologías y con dosis de fenoles ajustadas a los consumos habituales de VOO, deben desarrollarse, 
para lograr evidencia científica de alta calidad antes de que se puedan dar recomendaciones nutricionales al público en general.
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1. INTRODUCTION
In 2014, Francesco Visioli published an editorial 
response to a review by Tang et al., (2014) on the 
effects on cardiovascular health of resveratrol, 
a natural phenolic compound found in red wine 
(Visioli, 2014). Resveratrol was alleged to interact 
with multiple targets in a variety of cardiovascular 
disease models to exert protective effects or induce 
a reduction in cardiovascular risks. However, 
Visioli’s article was entitled “The resveratrol fiasco” 
and concluded that after more than 20 years of 
well-funded research, resveratrol had no proven 
human activity. He claimed that there was a lack of 
clinical trials and the majority of available evidence 
came from cell culture and animal models. He 
also suggested that the resveratrol fiasco is not the 
only one of that kind in pharma-nutrition research. 
Considering that the association of virgin olive oil 
(VOO) phenolic compounds and health was initiated 
in the late 90s (some of the early studies were carried 
out by Visioli himself (Visioli et al., 1998)) and that 
the bulk of experimental data were obtained from in 
vitro and animal models, are VOO phenolics another 
example of scientific fiasco? In order to answer 
this question, the present review summarizes the 
current knowledge on the effects of VOO phenolic 
compounds on human health, focusing on the data 
obtained from randomized clinical trials (RCT) and 
their meta-analyses and systematic reviews, which 
provide the highest level of scientific evidence.
2. VOO PHENOLIC COMPOUNDS
There is ample evidence indicating that VOO 
consumption provides benefits in key processes 
associated with the development of a number 
of diseases and pathophysiological conditions. 
These include atherosclerosis, diabetes mellitus, 
obesity, metabolic syndrome, cancer, arthritis and 
neurodegenerative diseases (Covas et al., 2015). 
Despite its high oleic acid content, VOO is more 
than just a monounsaturated fatty acid-rich fat. 
VOO contains minor compounds with potent 
pharmacological activity, which are classified 
into two large groups: those that form part of the 
unsaponifiable fraction and those with a phenolic 
nature. The former are lipophilic and may be 
extracted with organic solvents after saponification 
of the oil, while the latter are water soluble.
More than 30 phenolic compounds that can play 
a role in the health promoting qualities of VOO have 
been identified, among which there is considerable 
variation regarding their concentration (0.02 to 
600 mg/kg) (Servili et al., 2009). This variability 
depends on the type of phenolic compound, but also 
on many other factors such as the olive tree variety, 
geographical origin, cultivation techniques, ripening 
stage at the time of harvest, processing and storage. 
Among VOO phenolics, secoiridoids are present in 
the greatest amount, but the most interesting ones from 
the point of view of health are probably oleuropein 
aglycone and its metabolite hydroxytyrosol. 
However, the presence of oleocanthal should not be 
ignored, as this compound has received a great deal 
of attention since it was suggested that it might have 
anti-inflammatory activity (Beauchamp et al., 2005).
Several experimental studies in in vitro systems 
and animal models have shown that the possible 
benefits of VOO phenolics are associated with their 
anti-inflammatory, antioxidant and vasodilatory 
activity, which in theory makes them key preventive 
or therapeutic agents for metabolic diseases related 
to oxidative stress and inflammation (Covas et al., 
2006). However, most of these investigations used 
supraphysiological doses of phenolics (> 10 μM) 
(Catalán et al., 2015) and, therefore, it is difficult to 
translate their results into physiological relevance for 
humans. VOO phenolics are bioavailable in humans, 
i.e. they are susceptible to being absorbed and to exert 
a bioactive effect on the organism (de la Torre, 2008). 
It has been proposed that in humans hydroxytyrosol 
is dose-dependently absorbed and excreted in urine 
after the intake from VOO (Rubió et al., 2012; 
Oliveras-López et al., 2014). However, a more 
recent study in Sprague-Dawley rats suggested that 
different dosages of hydroxytyrosol do not provide 
a linear, dose-dependent plasma concentration or 
excretion in urine (Domínguez-Perles et al., 2017). 
Nevertheless, it has been estimated that the amount 
of phenolics ingested from VOO consumption does 
not exceed 9 mg/day in Mediterranean countries 
(Parkinson and Cicerale., 2016). 
Since 2011, the European Food Safety Authority 
(EFSA) accepts a claim about the benefits of daily 
intake of VOO rich in phenolic compounds over 
the oxidation of low density lipoproteins (LDL), 
maintenance of normal (fasting) blood levels of 
triglycerides, HDL-cholesterol and blood glucose 
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(EFSA Panel on Dietetic Products, Nutrition and 
Allergies (NDA), 2011). The acceptance of these 
claims by EFSA authorizes their inclusion on the 
labels of olive oil bottles. However, this health 
claim is focused on the protection provided by 
hydroxytyrosol and there are currently no accepted 
claims for the other benefits that have been attributed 
to VOO or its phenolic compounds. 
Although a large number of in vitro and 
experimental animal studies are available, according 
to Evidence-Based Medicine (Woolf et al., 1990), the 
healthy properties of a food and/or its components 
must be proved in RCT, in order to ensure that the 
alleged health benefits really stand out. The highest 
degree of scientific evidence is obtained through 
meta-analyses and systematic reviews of these RCT. 
However, at the moment the number and variety of 
RCT carried out using VOO phenolic compounds 
is very limited and there is only one meta-analysis 
and less than five systematic reviews assessing 
the healthy effects of VOO phenolic compounds. 
With regard to RCT, there are currently about 50 
published articles that can be classified as such in 
which the effect of VOO phenolic compounds on 
health has been evaluated. A high number of these 
studies were published by the group of Covas and 
their collaborators and the rest by three or four 
research teams, the absolute majority of which were 
Spanish or Italian.
3. VOO PHENOLIC COMPOUNDS AND 
CARDIOVASCULAR DISEASE
The role of VOO phenolics as cardiovascular 
protectors has been a matter of research for a long 
time. However, as very recently displayed by Visioli 
et al., (2020), most investigations used isolated 
compounds in pharmacological in vitro approaches, 
rather than more nutritional human trials. Still, 
enough data from human studies assessing surrogate 
markers of cardiovascular disease have been 
generated (Bogani et al., 2007; Visioli et al., 2005; 
Covas et al., 2006) to allow for the completion of a 
meta-analysis of RCT (Hohmann et al., 2015) and 
two systematic reviews (Bahramsoltani et al., 2019; 
Schwingshackl et al., 2019).
Indeed, this meta-analysis was aimed at assessing 
the effects of high phenolic olive oil on risk factors 
for cardiovascular disease. It was published in 2015 
and included the results of 8 human RCT (Hohmann 
et al., 2015). The sample size of these trials was quite 
variable, ranging from 24 participants in the study 
published by Moreno-Luna et al., (2012), to 200 
individuals in the one carried out by Covas et al., 
(2006). In addition, there was variability in the health 
status of the participants. In five of these studies, 
the subjects were healthy and in the remaining 
three ones, the recruited individuals already had 
a cardiovascular event. The doses used in these 
tests ranged from 0 to 19.5 mg of total phenolics. 
Furthermore, in all these trials what was compared 
was the intake of a high phenolic VOO with a refined 
olive oil. Therefore, only the total phenolic content 
was considered and the concentrations in different 
phenolic compounds were not distinguished.
The intake of high phenolic VOO only seemed to 
produce a modest but significant reduction in oxidized 
LDL-cholesterol (Z=1.98, p=0.05) and blood 
pressure (Z=4.04, p<0.001). For the rest of parameters 
related to cardiovascular disease (malondialdehyde, 
LDL-cholesterol, HDL-cholesterol, total cholesterol 
and triglycerides), no significant effects were found. 
Therefore, the conclusion of this meta-analysis was 
that a high phenolic VOO provides small beneficial 
effects on systolic pressure and plasma oxidative 
status. No association between the intake of phenolic 
compounds from VOO and cardiovascular risk could 
be obtained.
In addition to this meta-analysis, two 
systematic reviews were published, both of them 
in 2019. Bahramsoltani et al., (2019) published 
a comprehensive review about dietary phenolic 
compounds and atherosclerosis and, even more 
recently, Schwingshackl et al., (2019) carried out 
a systematic review and network meta-analysis to 
assess the impact of different types of olive oil on 
cardiovascular risk factors. 
The review by Bahramsoltani et al., (2019) 
included only six RCT, while the aforementioned 
meta-analysis by Hohmann and colaborators 
included eight. Of these 6 trials, only one reached 
a score of 3 on the Jadad Scale (Jadad et al., 1996) 
which measures the methodological quality of a 
clinical trial from 0 (very poor) to 5 (rigurous) points. 
The others stayed at 2 or below. What was observed 
in the best designed study (Covas et al., 2006) was 
an effect on the postprandial isoprostane F2 levels 
in plasma, which is a biomarker of oxidative stress. 
In this double-bind trial, 40 mL of three olive oils 
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with different phenolic contents were administered 
in a single dose: low (2.7 mg/kg), medium (164 mg/
kg) and high (366 mg/kg). The authors observed 
that the concentration in total phenolic compounds 
in LDL increased in the postprandial period in a 
direct relationship with the phenolic content of the 
oils ingested. Moreover, plasma concentrations 
of tyrosol, hydroxytyrosol, and 3-O-methyl-
hydroxytyrosol correlated with changes in the total 
phenolic compound contents in LDL. The other RCT 
included in the review also confirmed these results, 
as well as reduced lipid peroxidation (measured 
as 8-iso-PGF2α) and inflammation (assessed as 
intercellular adhesion molecule-1, ICAM-1).
The systematic review by Schwingshackl et al., 
(2019) included thirteen RCTs with 611 participants 
(mainly healthy) and compared refined olive oil, 
commercial olive oil (blend of refined and virgin 
olive oils), low-phenolic extra VOO and high-
phenolic VOO. No differences for total cholesterol, 
HDL-cholesterol, triglycerides, and diastolic blood 
pressure were observed. However, the phenolic 
content positively correlated with a slight reduction 
in LDL-cholesterol (mean difference -0.14 mmol/L, 
95%-CI: -0.28, -0.01) and oxidized LDL-cholesterol 
(standardized mean difference: -0.68, 95%-CI: -1.31, 
-0.04). Both, high- and low-phenolic VOO reduced 
systolic blood pressure compared to refined olive oil 
(range of mean difference: -2.99 to -2.87 mmHg). 
The authors concluded that high phenolic VOO may 
improve some cardiovascular risk factors, although 
the implications for public health were limited due 
to the overall low or moderate level of evidence 
provided and also because the duration of these RCTs 
was too short (≤12 weeks) and no data could be found 
for relevant outcomes such as cardiovascular events.
From these meta-analysis and systematic 
reviews, it can be concluded that the protective 
effect of VOO phenolics is related to blood pressure 
and LDL oxidation only. Nonetheless, although the 
oxidative hypothesis of atherosclerosis has been 
accepted for decades, the true contribution of LDL 
oxidation to cardiovascular disease is still unclear 
(Arsenault et al., 2017; Visioli et al., 2020). While 
the hypothesis is supported by hundreds of in vitro 
and animal studies, it does not explain why human 
trials with some antioxidants, such as vitamin E, 
did not provide sufficient convincing evidence 
for cardiovascular prevention (Sesso et al., 2008; 
Guallar et al., 2013). Possibly, the story is not as 
simple as it was believed. For instance, it has been 
proposed that LDL can become atherogenic even 
before oxidation. Modification of these lipoproteins 
begins with a desialylation and it is followed by a 
cascade of other physical and chemical alterations 
that increase LDL atherogenicity, including particle 
size reduction, increase in its density and negative 
electrical charge and loss of lipids (Summerhill et 
al., 2019). Therefore, the effects of VOO phenolics 
on cardiovascular disease via LDL modification are, 
as of today, dubious and there is need of more RCT 
that directly address the claim. 
4. VOO PHENOLIC COMPOUNDS AND 
TYPE 2 DIABETES MELLITUS/METABOLIC 
SYNDROME
Accumulated data obtained from experimental 
models indicate that VOO phenolics have the 
potential to normalize metabolic syndrome and 
its pathophysiological complications, including 
diabetes. Diabetes and metabolic syndrome are 
linked to each other through insulin resistance, 
and subjects diagnosed with metabolic syndrome 
have a high risk of developing T2DM (Shin et al., 
2013). However, there are currently no RCT aimed 
at specifically assessing the effect of VOO phenolics 
on Type 2 diabetes (T2DM) patients, although two 
systematic reviews on the effects of these compounds 
on metabolic syndrome have been published (Chiva-
Blanch and Badimon, 2017; Saibandith, 2017). 
The review by Chiva-Blanch and Badimon 
(2017) was focused on human intervention trials 
administering phenolic-rich foods to patients 
with metabolic syndrome. They included a single 
RCT, carried out by Venturini et al., (2015), which 
administered extra VOO (10 mL/day). That trial 
reported an increase in the total radical-trapping 
antioxidant parameter (TRAP)/uric acid ratio, with 
no apparent effects on other markers of oxidative 
stress. On the other hand, the authors did not find 
changes in the lipid profile, plasma glucose, insulin 
resistance or blood pressure. 
The systematic review by Saibandith et al., 
(2017) did assess the effects of VOO phenolics on 
components of the metabolic syndrome (i.e. glucose 
levels, blood pressure, central obesity, triglycerides 
and HDL-cholesterol). They summarized the current 
knowledge obtained from 18 clinical trials that were 
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not specifically aimed at this syndrome. Saibandith and 
collaborators confirmed the effects of VOO phenolics 
on systolic blood pressure observed in previous 
systematic reviews and meta-analyses, but they did not 
draw significant outcomes on obesity, triglycerides or 
HDL. Still, some reductions in plasma glucose and in 
biomarkers associated with glucose homeostasis were 
reported, but only in three of those trials. Surprisingly, 
the authors did not include the RCT by Venturini et 
al., (2015) that had been published a couple of years 
before, and therefore, they did not analyzed any 
RCTs involving patients with metabolic syndrome. 
The systematic review could only conclude that there 
was good evidence showing that, when consumed at 
appropriate doses, VOO phenolics may reduce blood 
pressure in hypertensive subjects and improve plasma 
glucose in pre-diabetic individuals.
It is noteworthy that the RCT involving patients 
with metabolic syndrome and published in 2016 by 
D’Amore et al., was not included in both systematic 
reviews stated above. In that trial, 12 subjects 
with metabolic syndrome and 12 healthy controls 
received a single dose of 50 mL VOO from two olive 
varieties: coratina, providing 491 ppm of phenolic 
compounds, and peranzana, which had 270 ppm of 
phenolics. The most interesting result found in this 
study was the modification of the transcriptome 
of peripheral blood mononuclear cells, switching 
them to a less deleterious inflammatory phenotype. 
However, no relevant changes in the components of 
the metabolic syndrome were observed.
5. VOO PHENOLIC COMPOUNDS AND 
ALZHEIMER’S DISEASE
AD is pathologically characterized by substantial 
neuronal and synaptic losses, and decreased 
cognitive abilities, which are associated with 
cerebral deposits of amyloid-beta-enriched plaques 
and neurofibrillary aggregates of the Tau protein, 
as well as with chronic inflammation and oxidative 
stress (Rosales-Corral et al., 2015) elicited by the 
pathological activation of glial cells (Scimemi et al., 
2013). Brain has revealed nowadays as an insulin-
sensitive organ, where the hormone regulates 
important physiological processes, such as nutrient 
homeostasis, reproduction, cognition, and memory, 
and also exerts neurotrophic, neuromodulatory, 
and neuroprotective effects (Blazquez et al., 2014). 
Disturbances in insulin signaling in the brain may 
contribute to the development of several clinical 
entities, including T2DM and Alzheimer’s disease. 
The close association between cerebral insulin 
resistance and Alzheimer’s Disease brought some 
authors to propose the name “type 3 diabetes” for 
this illness (de la Monte and Wands, 2008).
For the moment, there are no RCTs available 
in which olive oil phenolics have been tested on 
Alzheimer’s disease or other neurodegenerative 
disorders. Therefore, no systematic reviews or meta-
analysis of RCT have been performed so far. All 
available information refers to observational studies 
and those carried out in animal models, which, as 
mentioned above, provide a low level of scientific 
evidence.
Regarding the potential neuroprotective effects 
of olive phenolics, it has been reported that dietary 
supplementation with oleuropein aglycone reduced 
the amount of amyloid-beta oligomers in the brain of 
Alzheimer’s model mice (Luccarini et al., 2015), at 
the same time that they significantle improved their 
cognitive functions, presenting greater learning and 
memory capacities (Pantano et al., 2017). Oleuropein 
also enhanced the endogenous antioxidant response 
in the CA1 hippocampal area of rats suffering from 
colchicine-induced cognitive dysfunction, improving 
the redox status of glutathione, and increasing the 
activity of antioxidant enzymes, such as superoxide 
dismutase or catalase (Pourkhodadad et al., 2016). 
Similarly, hydroxytyrosol has been related to the 
amelioration of insulin resistance in the brain of mice 
(Kulas et al., 2020). In APP/PS1 mice, rodent models 
of AD, hydroxytyrosol improved cognitive function, 
increased the expression of antioxidant enzymes and 
phase 2 response genes, and reduced inflammatory 
factors in the brain of these animals (Peng et al., 2016).
Oleocanthal has also been associated with a 
reduction in amyloid-beta oligomers, as well as an 
attenuation of astrocytes activation and a reduction 
in systemic inflammation in neurons and astrocytes 
cells lines (Batarseh et al., 2017). Likewise, 
oleocanthal has demonstrated that it may modulate 
the astrocyte activation in TgSwDI mice, a model of 
Alzheimer’s disease (Qosa et al., 2015).
6. VOO PHENOLIC COMPOUNDS AND 
CANCER
Only one systematic review about the effects 
of VOO phenolic compounds on cancer has 
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the subjects informed a reduction in knee pain, as 
compared to the administration of a placebo.
8. CONCLUSIONS
The benefits of VOO phenolic compounds 
on health have been extensively investigated, 
and recent studies support the belief that these 
components may play a key role in the amelioration 
of pathophysiological conditions. In particular, 
studies on in vitro systems and animal models have 
shown that oleuropein derivatives, hydroxytyrosol 
and oleocanthal exert potent pharmacological 
activities on markers of cancer, atherosclerosis 
and metabolic diseases. More specifically, on 
those associated with inflammatory processes and 
oxidative stress. However, meta-analyses of RCT, 
from which the highest level of scientific evidence 
should be obtained, do not support those effects on 
humans, except for some markers of cardiovascular 
risk. In fact, the strongest piece of evidence available 
has been found for the ability of VOO phenolic 
compounds to protect lipoproteins from oxidation 
and to reduce systolic blood pressure in hypertensive 
individuals (Table 1).
Unfortunately, there is not enough high-level 
evidence at the moment to confirm that the intake 
of phenolic compounds isolated or as components 
of the VOO can be healthy (Table 2). No RCT have 
been carried out to assess the direct effect of VOO 
phenolics on diabetes or neurodegenerative diseases 
and very scarce information can be collected from the 
ones that have focused on osteoarthritis and cancer. 
Therefore, it is still necessary to develop double-bind 
RCT in extensive and diverse population groups, 
with different disorders and with doses of phenols 
adjusted to usual VOO consumptions, in order to 
provide a greater degree of scientific evidence before 
nutritional recommendations may be given to the 
general population.
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been published, which implies that there are no 
meta-analyses available and, in consequence, 
the highest level of scientific evidence cannot be 
reached. In their review, Fabiani et al., (2016) 
included 16 animal studies and 5 RCTs. Most 
of the animal studies confirmed the ability of 
secoiridoid compounds to inhibit carcinogenesis at 
both initiation and promotion/progression phases. 
However, all human intervention trials included in 
this review only investigated the effects of VOO 
phenolics on DNA damage and did not evaluate their 
effect on the incidence or development of any kind 
of cancer. These trials only reported determinations 
related to the oxidation of nucleic acids, in 
particular the concentrations of 8-oxo-7,8-dihydro-
2’-deoxyguanosine, which is a marker of DNA 
oxidation. Between 10 and 182 subjects participated 
in these RCT, and the phenolic doses from VOO 
ranged from 10 to 592 mg/kg. Three of the five 
human trials showed that VOO phenolics reduced 
the 8-oxo-7,8-dihydro-2’-deoxyguanosine levels in 
urine, mitochondrial DNA of mononuclear cells and 
lymphocyte DNA. The other two trials failed to find 
a protective effect on DNA oxidation. Four of these 
studies were conducted by the same research group, 
and had similar experimental designs (Weinbrenner 
et al., 2004; Hillestrøm et al., 2006; Machowetz 
et al., 2007; Romeu et al., 2016). Therefore, there 
is very little evidence relating the intake of VOO 
phenolic compounds with cancer. In fact, the authors 
suggested that further investigations are necessary 
to clarify the real chemopreventive potential of 
these compounds and that intervention studies on 
populations at high cancer risk are needed.
7. VOO PHENOLIC COMPOUNDS AND 
ARTHRITIS
There is currently only one RCT evaluating the 
effect of VOO phenolic compounds on arthritis 
(Takeda et al., 2013). This trial was aimed at 
determining whether hydroxytyrosol intake could 
reduce knee pain in individuals with gonarthrosis 
(n=25). An extract of Olea europaea containing 
approximately 22% of hydroxytyrosol, at a dose 
of 11 mg/day for 4 weeks, was administrated to the 
participants. The conclusion of the trial was that 
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Table 1. Availability of studies and degree of evidence for the effect of virgin olive oil phenolics intake on different disorders according 
to evidence-based medicine.















Alzheimer’s disease No No No Yes Yes Very low
Arthritis No No Yes
(1)
Yes Yes Low
Diabetes mellitus No No No Yes Yes Low






aNumbers in parentheses refer to the published number of studies of that kind. RCT, randomized controlled trial; BP, blood pressure; LDL, 
low-density lipoprotein.
Table 2. Summary of the studies cited in the text.
Disorder Study design n Intervention Dose (day)/time Time Main markers References
CVD RCT 22
2 olive oils 
(VOO vs ROO) 40 mL 7 weeks
TXB2, isopros-
tanes
Visioli et al., 
2005
RCT 200
3 olive oils 
(different PC) 25 mL 3 weeks TG, HDL, oxLDL
Covas et al., 
2006
RCT 12
EVOO, OO and 
CO 50 mL Postprandial TXB2, LTB4
Bogani et al., 
2007
RCT 24
2 olive oils 
















fferent PC) Various 3-12 weeks







fferent PC) Various 3-12 weeks





3 olive oils 




3 olive oils 






3 olive oils 




2 olive oils 
(different PC) 25 mL 3 weeks 8-OHdG




2-3 olive oils 
(different PC) 25 mL. 50 g
4 days – 8 
weeks 8-OHdG




cell line N/A Oleocanthal 5 μM 3-7 days
GLT1, GLUT1, 
IL-6













(TgSwDI) 6/group Oleocanthal 6 mg/kg injection 4 weeks Aß, IL-1ß
Qosa et al., 
2015
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